thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli
Company profile
Ticker
THMO
Exchange
Website
CEO
Xiaochun Xu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CESCA THERAPEUTICS INC., THERM0GENESIS CORP, THERMOGENESIS CORP
SEC CIK
Corporate docs
Subsidiaries
ThermoGenesis Corp. • Wholly-owned by ThermoGenesis Holdings, Inc. • CARTXpress Bio Inc. ...
IRS number
943018487
THMO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Other Events
19 Mar 24
8-K
Departure of Directors or Certain Officers
12 Mar 24
8-K
Entry into a Material Definitive Agreement
10 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 23
EFFECT
Notice of effectiveness
6 Dec 23
424B5
Prospectus supplement for primary offering
5 Dec 23
CORRESP
Correspondence with SEC
1 Dec 23
Transcripts
THMO
Earnings call transcript
2023 Q3
13 Nov 23
THMO
Earnings call transcript
2023 Q2
10 Aug 23
THMO
Earnings call transcript
2023 Q1
15 May 23
THMO
Earnings call transcript
2022 Q4
30 Mar 23
THMO
Earnings call transcript
2022 Q3
12 Nov 22
THMO
Earnings call transcript
2022 Q2
13 Aug 22
THMO
Earnings call transcript
2022 Q1
19 May 22
THMO
Earnings call transcript
2021 Q4
28 Mar 22
THMO
Earnings call transcript
2021 Q3
13 Nov 21
THMO
Earnings call transcript
2021 Q2
13 Aug 21
Latest ownership filings
4
Xiaochun Xu
19 Mar 24
SC 13D/A
Boyalife Group, Inc.
27 Nov 23
4
Xiaochun Xu
21 Nov 23
4
Xiaochun Xu
2 Oct 23
SC 13D/A
Boyalife Group, Inc.
14 Aug 23
3
James Xu
24 Jul 23
3
Biao Xi
24 Jul 23
SC 13D/A
Boyalife Group, Inc.
11 Apr 23
SC 13D/A
Xu Xiaochun
9 Mar 23
SC 13D/A
FOLEY & LARDNER/ FA
16 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.02 mm | 4.02 mm | 4.02 mm | 4.02 mm | 4.02 mm | 4.02 mm |
Cash burn (monthly) | 144.00 k | (no burn) | 519.00 k | 488.25 k | 83.67 k | 238.33 k |
Cash used (since last report) | 961.15 k | n/a | 3.46 mm | 3.26 mm | 558.45 k | 1.59 mm |
Cash remaining | 3.06 mm | n/a | 553.84 k | 759.09 k | 3.46 mm | 2.43 mm |
Runway (months of cash) | 21.2 | n/a | 1.1 | 1.6 | 41.3 | 10.2 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 2 |
Closed positions | 7 |
Increased positions | 5 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 919.14 mm |
Total shares | 58.47 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Boyalife Asset Holding II | 49.80 mm | $10.57 mm |
Boyalife | 3.04 mm | $13.57 mm |
Foley & LARDNER/ Fa | 2.76 mm | $10.14 mm |
Xu Xiaochun | 2.76 mm | $10.14 mm |
Raymond James & Associates | 50.00 k | $64.01 mm |
Vanguard | 35.42 k | $45.34 mm |
Citadel Advisors | 13.42 k | $16.78 mm |
MS Morgan Stanley | 9.29 k | $11.90 mm |
Tower Research Capital | 5.76 k | $7.37 mm |
BLK Blackrock | 1.49 k | $1.91 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Xu Xiaochun | Common Stock | Conversion | Acquire C | Yes | No | 0.38 | 4,113,158 | 1.56 mm | 4,440,279 |
15 Mar 24 | Xu Xiaochun | Amendment 4 to 1st Amended & Restated Revolving Credit Agr. Common Stock | Conversion | Dispose C | Yes | No | 0.38 | - | 1.56 mm | - |
17 Nov 23 | Xu Xiaochun | Common Stock | Sell | Dispose S | Yes | No | 1.02 | 600,000 | 612.00 k | 327,121 |
28 Sep 23 | Xu Xiaochun | Common Stock | Conversion | Acquire C | Yes | No | 1.07 | 654,206 | 700.00 k | 927,121 |
28 Sep 23 | Xu Xiaochun | Amendment 3 to 1st Amended & Restated Revolving Credit Agr. Common Stock | Conversion | Dispose C | Yes | No | 1.07 | - | 700.00 k | - |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
2 Apr 24
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
26 Feb 24
12 Health Care Stocks Moving In Monday's Intraday Session
26 Feb 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
26 Feb 24
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
8 Feb 24